View Older Stories View More Recent Stories

Apr 7, 2021 05:15AM PureTech Founded Entity Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Potential Treatme
Mar 26, 2021 08:08AM PureTech (PRTC) Founded Entity Akili Announces Results of EndeavorRx Clinical Study in Pediatric ADHD Published in Nature Digital Medicine
Mar 26, 2021 08:07AM PureTech Founded Entity Akili Announces the Results of EndeavorRx™ Clinical Study in Pediatric ADHD Published in Nature Digital Medicine
Mar 18, 2021 03:00AM PureTech Announces Board Member Retirement
Mar 15, 2021 03:00AM PureTech: Notice of Results
Mar 3, 2021 07:00AM PureTech to Present at The Barclays Global Healthcare Conference
Feb 25, 2021 09:17AM PureTech Announces Publication of Glyph™ Platform Preclinical Proof-of-Concept Study in Journal of Controlled Release
Feb 25, 2021 02:00AM PureTech Founded Entity Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia
Feb 18, 2021 07:00AM PureTech to Present at The SVB Leerink 10th Annual Global Healthcare Conference
Feb 10, 2021 06:25AM PureTech Health (PRTC) Receives Approximately $118 Million from Sale of Portion of Founded Entity Shares
Feb 10, 2021 02:00AM PureTech Founded Entity Vor Biopharma Closes Over $200M Initial Public Offering
Feb 10, 2021 02:00AM PureTech Receives Approximately $118 Million from Sale of Portion of Founded Entity Shares
Feb 8, 2021 07:00AM PureTech Founded Entity Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer
Feb 5, 2021 06:50AM PureTech Founded Entity Vor Biopharma Announces Pricing of Initial Public Offering
Jan 29, 2021 02:00AM PureTech Adds Bharatt Chowrira, PureTech’s President and Chief of Business and Strategy, to Board of Directors
Jan 14, 2021 07:11AM PureTech Health Plc (PRTC) Founded Entity, Vor Biopharma, Announces FDA Clearance of IND Application for VOR33
Jan 14, 2021 07:05AM PureTech Founded Entity Vor Announces FDA Clearance of IND Application for VOR33
Jan 14, 2021 06:50AM PureTech Founded Entity Follica Adds Two Leaders in Aesthetic Medicine and Dermatology to its Board of Directors
Jan 12, 2021 06:52AM PureTech (PRTC) Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
Jan 12, 2021 06:50AM PureTech Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
Jan 5, 2021 08:18AM PureTech Health Plc (PRTC) Names George Farmer CFO
Jan 5, 2021 02:00AM PureTech Announces the Appointment of George Farmer, Ph.D., as Chief Financial Officer
Dec 21, 2020 07:00AM PureTech to Present at 38th Annual J.P. Morgan Healthcare Conference and Other Conferences
Dec 11, 2020 07:00AM PureTech Advances Wholly Owned Candidate LYT-200 into Phase 1 Trial for Potential Treatment of Metastatic Solid Tumors
Dec 10, 2020 07:36AM PureTech Health Plc (PRTC) Begins Phase 2a trial of LYT-100 (Deupirfenidone) in Lymphedema
Dec 10, 2020 07:00AM PureTech Initiates Phase 2a trial of LYT-100 (Deupirfenidone) in Lymphedema
Dec 9, 2020 07:00AM PureTech Founded Entity Follica Announces Pilot Study for Female Pattern Hair Loss Published in International Journal of Women’s Dermatology
Dec 3, 2020 07:00AM PureTech Initiates Phase 2 trial of LYT-100 (Deupirfenidone) in Long COVID Respiratory Complications and Related Sequelae
Nov 30, 2020 07:00AM PureTech to Host Virtual R&D Day for Investors on December 11, 2020
Nov 24, 2020 07:00AM PureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors
Nov 18, 2020 06:07AM PureTech Health Plc (PRTC) Reports LYT-100 (Deupirfenidone) Demonstrates Tolerability and Pharmacokinetic Proof-of-Concept in Phase 1 Multiple Ascending Dose & Food Effect Study
Nov 18, 2020 02:00AM PureTech’s LYT-100 (Deupirfenidone) Demonstrates Tolerability and Pharmacokinetic Proof-of-Concept in Phase 1 Multiple Ascending Dose and Food Effect Study
Nov 16, 2020 02:00AM PureTech to Present at Three Upcoming Investor Conferences
Nov 5, 2020 02:00AM PureTech to Present at 29th Annual Credit Suisse Virtual Healthcare Conference
Oct 28, 2020 03:00AM PureTech Announces Public Filing of Registration Statement on Form 20-F for Planned U.S. Listing on Nasdaq Global Market
Oct 1, 2020 02:05AM PureTech Appoints Kiran Mazumdar-Shaw, Founder and Chairperson of a Leading Global Biopharmaceutical Company, to Board of Directors
Aug 5, 2020 02:00AM PureTech to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
Jun 22, 2020 09:00AM PureTech Presents New Data Reinforcing Galectin-9 as a Compelling Therapeutic Target and Biomarker for a Range of Cancers at the American Association for Cancer Research Annual Meeting
Jun 2, 2020 02:00AM Gelesis Receives Approval to Market PLENITY™ in Europe as a Weight Loss Treatment
May 28, 2020 02:00AM PureTech Advances LYT-100 (Deupirfenidone) for Treatment of Serious Respiratory Complications that Persist Following Resolution of COVID-19 Infection
May 27, 2020 02:00AM PureTech to Present at Jefferies Virtual Healthcare Conference
Apr 14, 2020 02:00AM PureTech to Present at 19th Annual Virtual Needham Healthcare Conference
Mar 10, 2020 06:01AM Gelesis Named One of the World’s Most Innovative Companies for 2020 by Fast Company
Mar 3, 2020 02:00AM PureTech Announces First Participant Dosed in Clinical Trial of Wholly-Owned Lymphedema Candidate LYT-100
Feb 18, 2020 02:00AM PureTech to Present at 9th Annual SVB Leerink Global Healthcare Conference
Dec 17, 2019 07:00AM Gelesis Announces Partnership with Ro on Commercial Launch of Plenity™
Dec 9, 2019 02:00AM Gelesis Secures Over $84 Million in New Capital to Support Commercialization of PLENITY™
Dec 5, 2019 02:00AM Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections
Nov 13, 2019 02:00AM PureTech to Present at Jefferies 2019 London Healthcare Conference
Nov 5, 2019 08:00AM PureTech Announces Presentation of New Data Supporting Wholly Owned Immuno-Oncology Programs LYT-200 (anti-galectin-9) and LYT-210 (anti-delta-1)
View More Recent Stories View Older Stories